Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Heron Therapeutics, Inc.NASDAQ: HRTX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 69.4%

Gross margin was 69.4% in Q1 FY2026, down 8.9 pp from a year earlier. On a trailing-twelve-month basis it was 71.1%, down 2.9 pp year over year. Over 3 fiscal years it widened by 24.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
69.4%-11.8 pp QoQ
Last fiscal yearDec 2025
73.3%+0.1 pp YoY
LTMMar 2026
71.1%-2.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-8.9 pp——
1 year+0.1 pp——
3 years+24.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
73.3%
Year-over-year change
+0.1pp

Gross Margin vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's LTM Mar 2026 gross margin of 71.1% is the 3rd highest of the 7 companies compared; the peer median is 65.0%.
  • Its year-over-year change of -2.9 pp is the 5th highest of 6, against a peer median of +4.5 pp.
  • Over three fiscal years its change of +24.3 pp compares with a peer median of -20.8 pp.
HRTX Competitors Peer median
Gross Margin for HRTX and competitors
Company Period LTM level YoY 3-year change
NTHINeonc Technologies Holdings, Inc.FY2025100.0% ——
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
HRTXHeron Therapeutics, Inc.LTM Mar 202671.1% -2.9 pp+24.3 pp
PLXProtalix BioTherapeutics, Inc.LTM Mar 202670.0% +20.0 pp-11.0 pp
CHRSCoherus Oncology, Inc.LTM Mar 202660.0% +4.5 pp-8.9 pp
OABIOmniAb, Inc.LTM Mar 202635.5% -64.5 pp-118.2 pp
MDWDMediWound Ltd.LTM Mar 202619.6% +5.2 pp-30.5 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding HRTX) 65.0%+4.5 pp-20.8 pp

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue86.35M107.67M127.04M144.29M154.9M
Cost of Revenue46.02M54.87M65.11M38.65M41.35M
Gross Profit40.33M52.8M61.94M105.64M113.56M
Gross Margin46.7%49.0%48.8%73.2%73.3%
Research & Development130.82M82.7M39.13M16.68M12.43M
Selling, General & Admin127.33M144.75M119.82M100.48M103.67M
Operating Expenses258.15M227.46M172.55M117.17M116.1M
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
EBITDA(215.25M)(176.66M)(103.79M)(5.06M)(17.88M)
EBITDA Margin-249.3%-164.1%-81.7%-3.5%-11.5%
Operating Income(217.83M)(174.66M)(110.62M)(11.53M)(2.54M)
Operating Margin-252.3%-162.2%-87.1%-8.0%-1.6%
Interest Income433K1.64M3.36M3.55M0
Interest Expense2.41M2.47M3.87M6.03M0
Other Income / Expenses(2.86M)(7.37M)56K(2.05M)(17.66M)
Income Before Tax(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Pre-Tax Margin-255.6%-169.1%-87.0%-9.4%-13.0%
Income Tax Expense00000
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Net Margin-255.6%-169.1%-87.0%-9.4%-13.0%
EPS (Basic)(2.24)(1.67)(0.80)(0.09)(0.12)
EPS (Diluted)(2.24)(1.67)(0.80)(0.09)(0.12)
Weighted Avg Shares98.47M109M138.14M152.45M166.71M
Weighted Avg Shares (Diluted)98.47M109M138.14M152.45M166.71M

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.